Patient with terminal cancer has total remission of the disease after treatment developed by Brazilian

A patient with end-stage prostate cancer, with a four-month life expectancy, achieved complete remission of the disease after undergoing an innovative treatment developed by a Brazilian physician.

Scott Miller was diagnosed with metastatic stage IV prostate cancer in July 2021 at the age of 66. The tumor was nearly 12 centimeters in diameter and had spread to bones, gallbladder, bladder, rectum and other organs.

The patient was treated for six months with BTT technology, which consists of inducing heat shock proteins by means of a controlled increase in temperature by the brain. Heat shock proteins are found in virtually all living organisms with diverse and complex functions.

The innovation was developed by Brazilian researcher Marc Abreu, a specialist in brain thermodynamics and thermoregulatory frequencies, graduated from the Federal University of São Paulo (Unifesp). The so-called cerebral thermal tunnel (BTT) was developed by the doctor at Yale University, in the United States.

The clinical case report was presented this Wednesday (26) at the 38th Annual Congress of the Society for Thermal Medicine, in San Diego, USA.

“Decreased heat shock protein expression is associated with cancer, neurological disease and aging. For the treatment of cancer, in addition to changing the thermodynamic load, we use different frequencies during induction in order to act in different areas. The modality is the same as the one we use in the treatment of neurological diseases, but the recipe is different”, explains Abreu.

Five inductions were required as treatment over six months. According to the clinical report, Miller did not experience any side effects and did not perform any additional treatment, that is, the patient did not undergo radiotherapy or chemotherapy at any time, traditional treatments to fight cancer.

“In the first induction, I already felt something different. With that, I moved temporarily from Los Angeles to Miami, where the BTT Medical Institute is located, to continue the treatment. After the treatment, my radiologist reviewed my scans and informed me that unbelievably it is as if I never had cancer,” says Miller.

The patient will be monitored every six months at the institute and will undergo batteries of tests for three years.

A very important point is that with this treatment we not only eliminate the cancer, but also the source of the cancer. We have the eradication of cancer stem cells and the neutralization of signaling molecules, which are the molecules that lead to the development and then the recurrence of cancer

Marc Abreu, specialist in brain thermodynamics and thermoregulatory frequencies

Treatment that performs the induction of heat shock proteins through brain-guided hyperthermia has also been used in patients with neurological diseases.

“We believe that our technology, based on the thermodynamics of the brain, has a unique potential to prevent and treat countless diseases at the molecular level”, says Abreu.

silent disease

Prostate cancer is considered a silent disease, which does not usually show signs or symptoms in the early stages. Some patients may experience symptoms such as difficulty urinating, decreased urine output, a greater need to go to the bathroom, in addition to the presence of blood in the urine.

The disease has variable evolution profiles, and may present a slow or fast growth, from one patient to another.

Touch examination is one of the screening methods for early detection of cancer. The test allows the doctor to check the structure of the prostate, as well as possible signs of enlargement or other changes. With aging, the prostate can increase in size naturally, without any kind of disease.

The Brazilian Society of Urology (SBU) recommends that men from 50 years old, and even without showing symptoms, seek medical attention, for individualized evaluation with the aim of diagnosing cancer early.

The touch exam can be performed annually from the age of 50 for the general population, and should be started at the age of 45 for men who are part of the risk group, especially those who have a family history of the disease.

To clarify the diagnosis, specialists also use another indicator called prostate-specific antigen (PSA). Although the protein is naturally produced by the gland, the increase in the level of PSA present in the circulation may indicate the need to investigate the presence of a tumor.

The PSA test is carried out from the collection of blood, which allows measuring the levels of the molecule in the body. The results are then compared by the doctor with other factors such as the size of the prostate, the patient’s age and the presence of nodules or inflammation in the prostate.